p.83 抽出テキスト

............................................................................. 418. Sennstrom M, Rova K, Hellgren M, Hjertberg R, Nord E, Thurn L, Lindqvist PG. Thromboembolism and in vitro fertilization - a systematic review. Acta Obstet Gynecol Scand 2017;96:1045–1052. 419. McLintock C, Brighton T, Chunilal S, Dekker G, McDonnell N, McRae S, Muller P, Tran H, Walters BN, Young L. Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period. Aust N Z J Obstet Gynaecol 2012;52:14–22. 420. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACS) in VTE treatment. J Thromb Thrombolysis 2016;41:206–232. 421. Friedrich E, Hameed AB. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol 2010;30:253–257. 422. Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995;50:534–541. 423. De Carolis S, di Pasquo E, Rossi E, Del Sordo G, Buonomo A, Schiavino D, Lanzone A, De Stefano V. Fondaparinux in pregnancy: Could it be a safe option? A review of the literature. Thromb Res 2015;135:1049–1051. 424. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004;350:1914–1915. 425. Beyer-Westendorf J, Michalski F, Tittl L, Middeldorp S, Cohen H, Abdul Kadir R, Arachchillage DJ, Arya R, Ay C, Marten S. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thromb Haemost 2016;116:651–658. 426. Garg J, Palaniswamy C, Lanier GM. Peripartum cardiomyopathy: Definition, incidence, etiopathogenesis, diagnosis, and management. Cardiol Rev 2015;23:69–78. 427. Tanaka K, Tanaka H, Kamiya C, Katsuragi S, Sawada M, Tsuritani M, Yoshida M, Iwanaga N, Yoshimatsu J, Ikeda T. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J 2016;80:2221–2226. 428. Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth weight. Am J Cardiol 1997;79:1436–1438. 429. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Dublin S, Platt R. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 2011;20:138–145. 430. Godfrey LM, Erramouspe J, Cleveland KW. Teratogenic risk of statins in pregnancy. Ann Pharmacother 2012;46:1419–1424. 431. Winterfeld U, Allignol A, Panchaud A, Rothuizen LE, Merlob P, Cuppers- Maarschalkerweerd B, Vial T, Stephens S, Clementi M, De Santis M, Pistelli A, Berlin M, Eleftheriou G, Manakova E, Buclin T. Pregnancy outcome following maternal exposure to statins: A multicentre prospective study. BJOG 2013;120:463–471. 432. U.S. Food & Drug Administration. Pregnancy and lactation labeling (drugs) final rule. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/Development Resources/Labeling/ucm093307.htm. 433. Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover B, Cook L, McElhatton PR, Schmidt MA, Koren G. The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study. Am J Obstet Gynecol 1996;174:823–828. 434. Weber-Schoendorfer C, Hannemann D, Meister R, Elefant E, Cuppers- Maarschalkerweerd B, Arnon J, Vial T, Rodriguez-Pinilla E, Clementi M, Robert- Gnansia E, De Santis M, Malm H, Dolivo A, Schaefer C. The safety of calcium channel blockers during pregnancy: A prospective, multicenter, observational study. Reprod Toxicol 2008;26:24–30. 435. Schaefer C. Angiotensin II-receptor-antagonists: Further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 2003;67:591–594. 436. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443–2451. 437. American Academy of Pediatrics Committee on Drugs. American Academy of Pediatrics Committee on Drugs: The transfer of drugs and other chemicals into human milk. Pediatrics 1994;93:137–150. 438. Andrade SE, Gurwitz JH, Field TS, Kelleher M, Majumdar SR, Reed G, Black R. Hypertension management: The care gap between clinical guidelines and clinical practice. Am J Manag Care 2004;10:481–486. 439. Podymow T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol 2011;31:70–85. Downloaded from academic.oup.com/eurheartj/article/39/34/3165/5078465 by guest on 07 October 2026